natgillin/translations-raw huggingface dataset:
In accordance with a preferred embodiment, the outlet for yeast enriched fraction 32 is situated above and downstream of the position where the flotation separation device receives the feed from outlet 22 . 
Uređaj prema Zahtjevu 11, gdje se odvod za frakciju (32) bogatu kvascem nalazi iznad i nizvodno od mjesta gdje uređaj za separaciju putem sedimentacije prihvaća tok iz odvoda (22).
Aspect 26. The elongate wick of aspect 25 wherein the polymeric material is a thermoset polymer. 
Izduženi fitilj (30) prema zahtjevu 22, pri čemu je polimerni materijal termostvrdnjujući polimer.
Method according to any one of claims 1 to 8, wherein the sample of known AD status is a sample of a patient with AD or a sample of a healthy person. 
Postupak prema bilo kojem od zahtjeva 1 do 8, naznačen time, da se u uzorku provodi korak demaskiranja na AB- specifičnim protutijelima, prije stavljanja u doticaj uzorka s AB-agregatima, posebno ako su otkrivena IgM- protutijela.
an insulin secretagogue, for use in a method of preventing or treating diabetes mellitus, diseases associated with diabetes mellitus, or complications of diabetes mellitus, wherein (A) and (B) are administered to a patient in need either simultaneously or separately. 
(B) metformina naznačena time da je za uporabu u postupku prevencije ili liječenja dijabetes melitusa, bolesti povezanih sa dijabetes melitusom, ili komplikacijama dijabetes melitusa, pri čemu se (A) i (B) daju pacijentu kojemu je to potrebno bilo istovremeno ili odvojeno.
The method of claim 26 or 28, wherein the domain or peptide or polypeptide capable of eliciting an immune response is selected from autoantigens, tumor antigens, virus antigens, parasite antigens, bacterial antigens and immunogenic fragments thereof. 
Postupak prema zahtjevu 26 ili 28, naznačen time što se domena ili peptid ili polipeptid sa sposobnošću izazivanja imunog odgovora, bira između autoantigena, tumorskih antigena, virusnih antigena, antigena parazita, bakterijskih antigena i njihovih imunogenih fragmenata.
The antibody, or a divalent functional fragment thereof, or the composition, for the use of claim 20, characterized in that said cancer is a cancer chosen from prostate cancer, osteosarcomas, lung cancer, breast cancer, endometrial cancer, glioblastoma or colon cancer. 
Antitijelo ili pripravak za upotrebu prema patentnom zahtjevu 11, naznačeno time da rečemi karcinom jest karcinom odabran od karcimoma prostate, osteosarkoma, karcinoma pluća, karcinoma dojke, karcinoma endometrija, glioblastoma ili karcinoma debelog crijeva.
The following couplings were used for the examples: 
CIJEVI ZA BUÅ OTINE SA POLIMERNIM OBLOGAMA
The process according to Claim 1, wherein the boronic acid in step (A) is a substituted or unsubstituted phenyl boronic acid; and/or wherein the boronic acid in step (A) is a phenyl boronic acid wherein R10 represents one or more substitutions for hydrogen independently chosen from: 
FI Postupak prema zahtjevu 1, gdje boronska kiselina u koraku (A) jest supstituirana ili nesupstituirana fenil boronska kiselina; i/ili gdje boronska kiselina u koraku (A) jest fenil boronska kiselina gdje R'" predstavlja jednu ili više supstitucija za vodik nezavisno izabranih između: 1)
a 5' homology arm that is homologous to a 5' target sequence at the genomic locus of interest; and a 3' homology arm that is homologous to a 3' target sequence at the genomic locus of interest, wherein following contacting the mouse ES cell with the Cas9 protein, the CRISPR RNA, and the tracrRNA in the presence of the LTVEC, the genome of the mouse ES cell is modified to comprise a targeted genetic modification comprising deletion of a region of the genomic locus of interest wherein the deletion is at least 30 kb and/or insertion of the insert nucleic acid at the genomic locus of interest wherein the insertion is at least 30 kb. 
(i) 5 homologonu ruku koja je homologna s 5* ciljnom sekvencom na genomskom lokusu od interesa; i (1i) 3 homologom rukom koja je homologna s 3? ciljnom sekvencom na genomskom lokusu od interesa, naznačeno time da nakon dovođenja u kontakt mišje ES stanice s Cas9 proteinom, CRISPR RNA, 1 tracrRNA u prisustvu LTVEC, genom mišje ES stanice je modificiran tako da obuhvaća ciljnu genetičku modifikaciju koja obuhvaća deleciju područja genomskog lokusa od interesa gdje je delecija najmanje 30 kb i/ili insercija inserta nukleinske kiseline na genomskom lokusu od interesa naznačeno time da je insercija najmanje 30 kb.
The preparation method of claim 7, wherein the water activity (Aw) of the dry stabilizing composition is Aw<0.3 or lower. 
Postupak pripreme sukladno patentnom zahtjevu 7, naznačen time da aktivnost vode (Aw) suhe stabilizirajuće kompozicije je Aw<0,3 ili niži.
The compound for use as claimed in claim 19, wherein the disease, disorder, or condition is selected from the group consisting of periodontal disease, chronic inflammatory airway disease, chronic bronchitis, and chronic obstructive pulmonary disease. 
Spoj za uporabu kako je zatraženo u zahtjevu 19, naznačen time da je bolcst, poremećaj ili stanje odabrano iz skupine koja se sastoji od periodontalne bolesti, kronične upalne bolesti dišnih puteva, kroničnog bronhitisa, te kronične opstruktivne plućne bolesti.
A cylinder lock and key system according to claim 4 and 5, wherein the first edge (210,1010,1110) of the key blade is an edge which, in the fully inserted position, is positioned proximal to the radially closed end of the keyway. 
Sustav cilindar brave 1 ključa prema zahtjevu 2 i 3, naznačen time što prvi rub (210, 10 10, 1110) oštrice ključa je rub koji je, u potpuno umetnutom položaju, postavljen proksimalno na radijalno zatvoreni kraj ključanice.
providing a ceramic base body which is unfired or has undergone preliminary firing, 
osiguravanje osnovnog keramičkog tijela koje nije pečeno ili je bilo podvrgnuto prethodnom pečenju, -
The rodent of clause 19, wherein the rodent is a mouse. 
Glodavac iz zahtjeva 1., pri čemu je glodavac miš.
raw material for the preparation of a preform, 
- < sirovi materijal za pripremu predoblika
The polypeptide of any preceding claim wherein the first proximal end does not disrupt a short repeat-long repeat-short repeat portion. 
Polipeptid u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time što prvi proksimalni kraj ne prekida dio s kratkim ponavljanjem-dugim ponavljanjem-kratkim ponavljanjem.
Preferably the seal coat is made of an Opadry coating, particularly preferably it is Opadry White, and more particularly preferably it is Opadry White OY-S-28876. 
Poželjno brtvena ovojnica je načinjena od Opadry obloge, naročito poželjno ona je Opadry White, 1 još naročito poželjnije ona je Opadry White OY-S-28876.
When button 113 is released, the motor speed for pump motor 42 will be set. 
Kada se gumb 113 oslobodi, podešena je brzina motora 42 pumpe.
A preventive or a remedy for ocular hypertension comprising a Rho kinase inhibitor and a carbonic anhydrase inhibitor in combination. 
Preventivno ili ljekovito sredstvo protiv povišenog očnog tlaka, naznačeno time, da sadržava mhibitor Rho kinazu i inhibitor ugljičnu anhidrazu u kombinaciji.
Process for the preparation of the capsule according to claims 10 or 11, which includes the addition of the pharmaceutical formulation of claims 1 to 9 to one of the two cavities of the open capsule and sealing of the capsule. 
Postupak priprave kapsule u skladu s patentnim zahtjevima 10 ili 11, naznačen time što uključuje punjenje farmaceutske formulacije u skladu s patentnim zahtjevima 1 do 9 u jednu od dvije šupljine otvorene kapsule, te hermetičko zatvaranje kapsule.
Item 4. A pharmaceutical composition comprising as active ingredient a therapeutically effective amount of a salt according to item 1, 2 or 3, in association with at least one pharmaceutically acceptable excipient, carrier or diluent. 
Farmaceutski pripravak naznačen time da kao aktivni sastojak sadrži terapijski učinkovitu količinu soli prema zahtjevu 1, 2 ili 3, u kombinaciji s najmanje jednom farmaceutski prihvatljivom pomoćnom tvari, nosačem ili dodatkom za otapanje.
In contrast, the active agent is more susceptible to hydrolysis and is more susceptible to evaporation in a crystalline matrix, such as those of known non-gel lozenges. 
Nasuprot tome, aktivno sredstvo je podložnije hidrolizi i podložnije je isparavanju u kristalnom matriksu, kao što su ona u poznatim tabletama koje nisu u obliku gela.
In yet another embodiment, the dispersible polymer may be added to the adhesive composition at a ratio of between 5-300% of the mass of the expanded perlite. 
Pripravak u skladu s patentnim zahtjevom 1, naznačen time, što je spomenuti prašak za disperzibilni polimer u omjeru između 5-300% mase navedenog proširenog perlita.
A combined product comprising the antitumor agent according to claim 9 and a cancer chemotherapeutic agent. The combined product according to claim 13, wherein the cancer chemotherapeutic agent is an antitumor agent having TS inhibitory action. 
Kombinirani proizvod prema zahtjevu 13, naznačen time, da se kod kemoterapeutskog sredstva protiv raka, radi o antitumorskom sredstvu koje ima inhibitorsko djelovanje na TS (sintazu timidilata).
to enclose all the components of the apparatus, including the data-processing system, in a single cabinet, in order for the apparatus to be compact and safer; 
- < obuhvaćanje svih komponenti ovog uređaja, uključujući sustav za obradu podataka, u samo jedan ormarić, da bi na taj način uređaj bio kompaktan i sigurniji; HR P20080238 T3
the amino, aminocarbonyl, and aminosulfonyl optionally are substituted with: 
(a) amino, aminokarbonil i aminosulfonil su po izboru supstituirani s:
The process of claim 4, wherein the organic solvent of step i) is dichloromethane, and the compound (V) isolated in step iii) is compound (IV) in polymorphic Form A: 
Postupak prema zahtjevu 4, gdje organsko otapalo u koraku 1) jest diklorometan, i spoj (V) izoliran u koraku 111) jest spoj (TV) u polimorfnom obliku A:
Use according to claim 1, wherein the topical medicament comprises 0.1% by weight of adapalene and 2.5% by weight of benzoyl peroxide and is to be applied to the afflicted skin once daily. 
Upotreba u skladu s patentnim zahtjevom 1, naznačena time što topikalni medikament sadrži 0,1%, težinski, adapalena i 2,5%, težinski, benzoil-peroksida i što ga treba primjenjivati na oboljelu kožu jednom dnevno.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidene-benzonorbornene-5-yl)amide and as component (B) mandipropamid. 
Spoj prema zahtjevu 1, naznačen time, da sadrži kao komponentu (A) spoj (9-difluorometiliden-benzonorbornen-5-iljamid 3-difluorometil-1-metil-1H-pirazol-4-karboksilne kiseline, te kao komponentu (B) fenpropidin.
A conjugate for use in medicine, the conjugate comprising an L-asparaginase from Erwinia chrysanthemi having at least 90% identity to the amino acid sequence of SEQ ID NO:1 and polyethylene glycol (PEG), wherein the PEG has a molecular weight less than or equal to about 5000 Da. 
Konjugat za upotrebu u medicini, pri čemu konjugat sadrži L-asparaginazu iz Erwinia chrysanthemi koja je barem 90% identična aminokiselinskoj sekvenci SEQ ID NO: 1 i polietilen glikol (PEG), naznačen time da PEG ima molekularnu masu manju ili jednaku oko 5000 Da.
ISO 1520: 1999 as a function of the 
Broj objave europskog patenta:
To a stirred solution of 3-hydroxycyclopentane-1,1-dicarboxylic acid diethyl ester (0.85 g, 0.0037 mole) in ethanol (7 mL), a solution of sodium hydroxide (0.162 g, 0.0040 mole) in water (3 mL) is added at room temperature. 
COOEt U miješanu otopinu dietilnog estera 3-hidroksiciklopentan-1,1-dikarboksilne kiseline (0,85 g, 0,0037 mol) u etanolu (7 ml) doda se otopina natrijevog hidroksida (0,162 g, 0,0040 mol) u vodi (3 ml) na sobnoj temperaturi.
The bonding spots and/or boding areas are formed by a method wherein shell and cup wall are pressed together at least at one of such bonding spots and/or one of such bonding areas within said contact path. 
Ovi su načinjeni samo lokalno pomoću odgovarajućeg postupka kod kojega su ljuska i stijenka čaše pritisnuti zajedno najmanje na jednoj od takvih točaka spajanja i/ili na jednom od takvih predjela spajanja, pri čemu su točke ili predjeli smješteni unutar staze za kontakte.
A process as claimed in claims 5 to 9 comprising the step of monitoring the temperature in the poultry shed and controlling the temperature of the environment in the poultry shed by regulating the flow of heated liquid to the radiator element. 
Postupak sukladno Zahtjevima 5 ili 6, koji obuhvaća korak praćenja temperature prostora za uzgoj gljiva (3), te kontrolu temperature okoline u prostoru za uzgoj gljiva (3) reguliranjem protoka ugrijane tekućine u element za zagrijavanje (15).
The method of claim 1, wherein the antibody is a recombinant antibody, a chimeric antibody, a humanized antibody, a human antibody, an antibody fragment, a bispecific antibody, a monospecific antibody, a monovalent antibody, an IgG1 antibody, or an IgG2 antibody. 
Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time, da protutijelo je kimerno protutijelo, humanizirano protutijelo, ljudsko protutijelo, fragment protutijela, bispecifično protutijelo, monospecifično protutijelo, monovalentno protutijelo, IgG 1-protutijelo ili IzG2-protutijelo.
A polypeptide comprising SEQ ID NO: 60 or 62. 
Polipeptid naznačen time da sadrži SEQ ID NO: 60 ili 62.
exposing a genetically modified mouse to an antigen, wherein the genetically modified mouse has a genome that comprises an endogenous k light chain immunoglobulin locus comprising a replacement of endogenous Vk and Jk gene segments with human Vλ and Jλ gene segments, wherein the human Vλ and Jλ gene segments are operably linked to a mouse Ck gene such that the mouse expresses an immunoglobulin light chain that comprises a human λ variable sequence fused with a mouse k constant region; 
Genetski modificirani miš prema zahtjevu 1, naznačen time, što miš u svom genomu dodatno sadrži endogeni lokus imunoglobulina lakog lanca K koji se sastoji od zamjene endogenih VK 1 JK genskih segmenta neraspoređenim humanim VA i JA genskim segmentima, te naznačen time, što su humani VA 1 JA genski segmenti operativno povezani s endogenim mišjim CK genom tako da miš izražava imunoglobulinski laki lanac koji sadrži humanu varijabilnu regiju A spojenu s mišjom konstantnom regijom K.
The compound of paragraph 6 wherein the compound is 3-chloro-4-(6-hydroxyquinolin-2-yl)benzoic acid. 
Spoj ili sol prema zahtjevu 6, naznačen/a time, da spoj je 3-kloro-4-(6-hidroksikinolin-2-il)benzoeva kiselina.
WO 91/14468 A1 and WO 97/12687 A1 relate to an atomiser with a spring pressure of 5 to 60 MPa, preferably 10 to 50 MPa, on the fluid, with a volume per stroke of 10 to 50 µl, preferably 10 to 20 µl, most preferably about 15 µl per stroke, and particle sizes of up to 20 µm, preferably 3 to 10 µm. 
WO 91/1446 A1 i WO 97/12687 A1 odnose se na atomizer s tlačnom oprugom koja djeluje na fluid s 5 do 60 MPa, ponajprije 10 do 50 MPa, s volumenom po udaru od 10 do 50 ul, ponajprije 10 do 20 pi, ponajbolje pribl. 15 ml po udaru, i veličine čestica sve do 20 um, ponajprije 3 do 10 um.
responsive to receiving the data transfer request, the firmware determining (506) whether the receiver has an empty buffer to be able to receive the data; 
odgovaranje na primanje zahtjeva za prijenos podataka, firmware određuje (506) ima li primatelj prazan ublaživač za primanje podataka;
A compound according to claim 1, wherein the compound is or an enantiomer, diastereomer, tautomer, or pharmaceutically acceptable salt or solvate thereof. 
Tvar u skladu s patentnim zahtjevom 1, pri čemu je tvar [image] ili enantiomer, dijastereoizomer, tautomer, ili njena farmaceutski prihvatljiva sol ili solvat.
B1, B2 are independently adenine, guanine, thymine, cytosine, uracil or modified nucleobases; and 
B,1iB, su nezavisno adenin, guanin, timin, citozin, uracil ili modificirane nukleobaze.
A compound of claim 1, wherein m is 0 or 1; and R2a is hydrogen. 
Spoj u skladu s patentnim zahtjevom 1, naznačen time, da je m 0 ili 1 i R2a je vodik.
The reaction mixture is diluted with water (3 ml) and extracted with ether (3 x 15 ml). 
Reakcijsku smjesu se razrijedi s vodom (3 ml) 1 ekstrahira s eterom (3 x 15 ml).
In another embodiment, Ra is TBDMS. In another embodiment, the process comprises a further deprotection step; for instance, when ring A is wherein Ra is a silyl protecting group, to generate a compound of Formula (I), wherein ring A is 
Postupak prema zahtjevu 33 naznačen time da dodatno sadrži reakciju deprotekcije kada prsten A je (ili (d) naznačen time da R* je silil zaštitna skupina, da de dobije spoj sa formulom (1), pri čemu prsten A je;
wherein Ra, Rb and Rc are as defined herein. In certain embodiments of formula I, R1 is a group of formula A3: 
Spoj prema zahtjevu 1, naznačen time, da R' je skupina formule A1, formule A2 ili formule A3:
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) chlorothalonil. 
Pripravak prema zahijevu 1, naznačen time da sadrži kao komponentu (A) spoj 3-difluoromelil-1-melil-1Hpirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-iljamid, a kao komponentu (B) biksafen.
A pharmaceutical composition comprising the compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle. 
Farmaceutski pripravak naznačen time što sadrži spoj ili sol prema patentnom zahtjevu 5 i farmaceutski prihvatljiv nosač, adjuvant ili medij.
a container containing a pharmaceutical composition according to any of claims 1 to 13, in solution or in lyophilized form; 
Farmaceutski sastav prema bilo kojem od zahtjeva 1 do 11 za uporabu kao cjepivo protiv karcinoma.
An antisense oligonucleotide for use in a method for treating Hutchinson-Gilford progeria syndrome in a subject, comprising administering the antisense oligonucleotide to a subject in need thereof, wherein the oligonucleotide inhibits expression of mutant LMNA protein mRNA, the oligonucleotide having a substantially uncharged backbone and being composed of morpholino subunits and phosphorus-containing intersubunit linkages joining a morpholino nitrogen of one subunit to a 5'-exocyclic carbon of an adjacent subunit, containing 25-40 bases; and comprising a targeting sequence comprising any one of SEQ ID NOs: 4, 5, 10, 11, 13, 14, and 16, wherein the antisense oligonucleotide is covalently attached to a cell-penetrating peptide and linker moiety, wherein the linker moiety is selected from glycine, cysteine, proline, 6-aminohexanoic acid (Ahx), B-alanine (B), and Ahx-B, and the cell-penetrating peptide is selected from SEQ ID NOs: 39-54. 
Protusmjerni oligonukleotid za smanjenje ekspresije abnormalno upletene LMNA mRNA, te oligonukleotid ima uglavnom nanabijenu okosnicu i sastavljen je od morfolino podjedinica i veza između podjedinica koje sadrže fosfor koje spajaju morfolino dušik jedne podjedinice na 5'-egzociklički ugljik susjedne podjedinice, koji sadržava 25-40 baza, te koji sadrži ciljajuću sekvencu koja sadrži bilo koju od SEQ ID NOs: 4, 5, 10, 11, 13, 14, i 16, pri čemu je protusmjerni oligonukleotid kovalentno vezan na peptid koji prodire u stanicu i skupine poveznice, pri čemu je skupina poveznice odabrana iz niza koji čine glicin, cistein, prolin, 6-aminoheksanoična kiselina (Ahx), B-alanin (B), i Ahx-B, te peptid koji prodire u stanicu je odabran od SEQ ID NOs: 39-54.
The compound as claimed in claim 12 or 13, or a salt or ester thereof, wherein R1 is a hydrogen atom or a group of -Q3-A3(R1d)R1e, and in the group of -Q3-A3(R1d)R1e; 
[image] Spoj prema zahtjevu 9 ili 10, ili njegova sol ili ester, gdje R1c je atom vodika ili skupina -Q3-A3(R1d)R1e, i u skupini -Q3-A3(R1d)R1e;
said carboxylic acid is selected from the group consisting of aliphatic and aromatic carboxylic acids, particularly benzoic acid. 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedenu karboksilnu kiselinu se bira iz skupine koju čine alifatske i aromatske karboksilne kiseline.
The organic phase was washed with water and the solvent was removed under reduced pressure. 
Organska faza se ispere s vodom i otapalo se ukloni pri sniženom tlaku.
A method according to claim 11 wherein the RD114-TR is integrated using a SIN lentiviral vector comprising an expression cassette containing from 5' to 3' end a CMV promoter the B-globin intron containing an RRE element in its sequence and the RD114-TR ORF. 
Metoda prema zahtjevu 11 naznačena time da je RD114-TR integriran koristeći SIN lentivirusni vektor koji se sastoji od kazete za ekspresiju koja sadrži od 5 'do 3’ kraja CMV promotora B- globinski intron s RRE elementom u svome slijedu i ORF RD114-TR.
Free base 
Slobodna baza Ž
each independently represents an unsubstituted or substituted C1-8 alkyl group, an unsubstituted or substituted C2-8 alkenyl group, an unsubstituted or substituted C2-8 alkynyl group, an unsubstituted or substituted C3-8 cycloalkyl group, an unsubstituted or substituted C4-8 cycloalkenyl group, an unsubstituted or substituted C6-10 aryl group, an unsubstituted or substituted heterocyclic group, an unsubstituted or substituted C1-8 acyl group, an unsubstituted or substituted (1-imino)C1-8 alkyl group, an unsubstituted or substituted carboxyl group, an unsubstituted or substituted carbamoyl group, an unsubstituted or substituted hydroxyl group, an unsubstituted or substituted amino group, an unsubstituted or substituted mercapto group, a substituted sulfonyl group, a halogeno group, a cyno group, or a nitro group; 
R> svaki neovisno predstavlja nesupstituiranu ili supstituiranu skupinu C,g alkil, nesupstituiranu ili supstituiranu skupinu C2s alkenil, nesupstituiranu ili supstituiranu skupinu Cxg alkinil, nesupstituiranu ili supstituiranu skupinu C3.g cikloalkil, nesupstituiranu ili supstituiranu skupinu Ca g cikloalkenil, nesupstituiranu ili supstituiranu skupinu CÂ«_1o aril, nesupstituiranu ili supstituiranu heterocikličku skupinu, nesupstituiranu ili supstituiranu skupinu C,_.g acil, nesupstituiranu ili supstituiranu skupinu (1-imino)C,.g alkil, nesupstituiranu ili supstituiranu karboksilnu skupinu, nesupstituiranu ili supstituiranu karbamoil skupinu, nesupstituiranu ili supstituiranu hidroksilnu skupinu, nesupstituiranu ili supstituiranu amino skupinu, nesupstituiranu ili supstituiranu merkapto skupinu, supstituiranu sulfonil skupinu, halogenu skupinu, cijano skupinu, ili nitro skupinu; n predstavlja broj od R? i cijeli je broj od 0 od 5;
The pharmaceutical composition of claim 2 comprising a compound of formula IIB, or a pharmaceutically acceptable salt, solvate, stereoisomer and/or ester thereof, wherein R13 is -(CH2)0-3CR17R18NR20R21 or -(CH2)0-3CR17R18NR17C(O)-NR20R21. 
Farmaceutski sastav prema patentnom zahtjevu 2, koji sadrži spoj formule IIB, ili njegovu farmaceutski prihvatljivu sol, solvat, stereoizomer i/ili ester, pri čemu R13 je-(CH2)0-3CR17R18NR20R21 ili-(CH2)0-3 CR17R18NR17C(O)-NR20R21.
Further, bacterial stability is higher and the risk of contamination with harmful and spoilage bacteria is lower. 
Nadalje, stabilnost prema bakterijama je veća, pa je i manji rizik od kontaminacije štetnim bakterijama i bakterijama koje uzrokuju kvarenje.
A HER2 antibody selected from the group consisting of trastuzumab and pertuzumab; 
HER2-protutijelo odabrano iz skupine koja se sastoji od trastuzumaba i pertuzumaba;
188 ml 6N NaOH was added dropwise at room temperature for 1 hour and the solution was allowed to stand for 12 hours. 
Postepeno se tijekom 1 sat pri sobnoj temperaturi doda 188 ml 6 N NaOH 1 otopina se pusti stajati 12 sati.
q ranges from 1 to 4, and Ab is an antibody or a fragment or derivative thereof. 
E O q je u rasponu od 1 do 4, a Ab je protutijelo ili njegov fragment ili derivat.